Aktuellt
SENASTE
Redeye gives its initial comments on the Q3 2024 report from Scandinavian ChemoTech, which was mostly in line with our estimates. Sales came in at SEK1.5m, against our forecasetd SEK1.9m, although the deviation is small in absolute amounts. We expect to make only minor changes to our estimates.
LÄS MER
